Damon Runyon News

Rachael A. Clark, MD, PhD (Damon Runyon Clinical Investigator ‘08-‘13) of Brigham and Women’s Hospital, Boston, and colleagues reported that the drug Campath (alemtuzumab) effectively treats patients with Leukemic cutaneous T-cell lymphoma (L-CTCL), a leukemia arising from a type of white blood cell called T-cells. This cancer can involve the skin and other organs, and patients often die within three years.

Maura L. Gillison, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘00-‘05) of the Ohio State University Comprehensive Cancer Center, Columbus, and colleagues reported that the prevalence of oral HPV (human papillomavirus) infection is about 7 percent in the United States. The prevalence was higher among men than among women.  HPV-16, the high-risk strain linked to throat cancers and many cervical cancers, is detected in 1 percent of people. The authors identified smoking and sexual behavior as risk factors for HPV infection.

In two parallel studies, Ralph J. DeBerardinis, MD, PhD (Damon Runyon Clinical Investigator ‘11-‘14) of UT Southwestern Medical Center, Dallas, and Matthew G. Vander Heiden, MD, PhD (Damon Runyon-Rachleff Innovator ‘11-‘13, Fellow ‘06-‘08) of MIT, Cambridge, and colleagues, reported the use of noninvasive imaging technology (magnetic resonance spectroscopy) to visualize whether glioma brain tumors have a particular genetic mutation called IDH.

Catherine J. Wu, MD (Damon Runyon Clinical Investigator ‘07-‘12) and Matthew L. Meyerson, MD, PhD (Damon Runyon Fellow ‘95-‘98) of Dana-Farber Cancer Institute, Boston, led the first large-scale genomics study of chronic lymphocytic leukemia (CLL). In tumor samples from 91 patients, they identified nine commonly mutated genes – five of which have been linked to CLL for the first time. One of these genes, SF3B1, is required for gene splicing (RNA processing), connecting the process to disease progression.

David E. Lebwohl, MD (Damon Runyon Fellow ‘86-‘87) of Novartis, East Hanover, and colleagues, reported results of a Phase III clinical trial testing the treatment combination of everolimus (Afinitor), which blocks a protein known to affect blood vessel growth in cancer cells, and the hormone therapy exemestane (Aromasin). 724 metastatic breast cancer patients with hormone receptor-positive tumors were enrolled in the trial. Patients who received the combination survived progression-free for twice as long as those who only received exemestane (7.4 months vs. 3.2 months).

Ralph J. DeBerardinis, MD, PhD (Damon Runyon Clinical Investigator ‘11-‘14) of UT Southwestern Medical Center, Dallas, and colleagues, discovered a metabolic pathway unique to some tumors. The tumor-specific pathway is dependent on the amino acid glutamine and reverses many of the chemical reactions of the Krebs cycle, used by normal cells. This new finding could provide a new target for drugs that could specifically target cancer cells without harming healthy cells. The study was published in the scientific journal Nature.

Mark A. Lemmon, PhD (Damon Runyon Scholar ‘97-‘98, Damon Runyon Fellow ‘93-‘96) of University of Pennsylvania, Philadelphia, and colleagues, reported new findings that will allow physicians to identify which neuroblastoma patients are most likely to respond to crizotinib (Xalkori). The drug was recently approved for treatment of certain lung cancers. It targets a protein called anaplastic lymphoma kinase (ALK) which is mutated in about ten percent of children with deadly neuroblastoma tumors.

Naoko Kobayashi, PhD (Damon Runyon Fellow ‘91-‘94) and colleagues at University of California, Los Angeles, reported results of a short-term Phase II clinical trial demonstrating anti-cancer benefits of fish oil. Men who ate a low-fat diet with fish oil supplements for four to six weeks before having their prostate removed had slower cancer cell growth in their prostate tissue than men who ate a typical high-fat Western diet. The researchers plan to expand this study to a larger group of men who will be monitored over an extended period of time (one year).

A team of researchers including Wendy S. Garrett, MD, PhD (Damon Runyon Fellow ‘06-‘09), Matthew L. Meyerson, MD, PhD (Damon Runyon Fellow ‘95-‘98), Akinyemi I. Ojesina, MBBS, PhD (Damon Runyon Fellow ‘08-‘11) and Ramesh A. Shivdasani, MD, PhD (Damon Runyon Scholar ‘98-‘99) at Dana-Farber Cancer Institute and the Broad Institute, Cambridge, reported high levels of a specific type of bacteria, Fusobacterium, in colorectal tumor samples.

Judith Lieberman, MD, PhD (Damon Runyon Fellow ‘84-‘86) of the Immune Disease Institute and Harvard Medical School, Boston, and colleagues, reported the first description of competing endogenous RNAs (ceRNAs) and their function. ceRNAs comprise a complex regulatory network that controls gene expression through binding of other RNAs called microRNAs. This study demonstrated that PTEN, a tumor suppressor, is regulated by 150 ceRNAs in human prostate and colon cancer cell lines. A separate study linked ceRNA-mediated regulation of PTEN to glioblastoma brain cancer.